trisporal capsules
janssen pharmaceutica (pty) ltd - capsules - see ingredients - each capsule contains itraconazole 100,0 mg
itraconazole 10mg/ml oral solution
athlone pharmaceuticals limited - itraconazole - oral solution - triazole derivatives; itraconazole
vicomyl 200 mg iv #n/a
viatris south africa (pty) ltd - #n/a - not indicated - none
vfend
pfizer new zealand limited - voriconazole 200mg; ; - film coated tablet - 200 mg - active: voriconazole 200mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white oy-ls-28914 povidone pregelatinised maize starch purified water - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.
vfend
pfizer new zealand limited - voriconazole 50mg; ; - film coated tablet - 50 mg - active: voriconazole 50mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white oy-ls-28914 povidone pregelatinised maize starch purified water - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.
vfend
pfizer new zealand limited - voriconazole 200mg; ; - powder for injection - 200 mg - active: voriconazole 200mg excipient: sulfobutyl betadex sodium water for injection - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.
vfend
pfizer new zealand limited - voriconazole 40 mg/ml; ; - powder for oral suspension - 40 mg/ml - active: voriconazole 40 mg/ml excipient: citric acid colloidal silicon dioxide orange flavour 57458 ap05514 sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.
itranol
rafa laboratories ltd - itraconazole - capsules - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis.
vfend 50 mg film-coated tablets
pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - voriconazole - treatment of:- invasive aspergillosis,- fluconazole-resistant serious invasive candida infections (including c. krusei) - serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
vfend 50 mg film-coated tablets
pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - voriconazole - treatment of:- invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei)- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.